Your browser doesn't support javascript.
loading
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.
Neidich, Scott D; Fong, Youyi; Li, Shuying S; Geraghty, Daniel E; Williamson, Brian D; Young, William Chad; Goodman, Derrick; Seaton, Kelly E; Shen, Xiaoying; Sawant, Sheetal; Zhang, Lu; deCamp, Allan C; Blette, Bryan S; Shao, Mengshu; Yates, Nicole L; Feely, Frederick; Pyo, Chul-Woo; Ferrari, Guido; Frank, Ian; Karuna, Shelly T; Swann, Edith M; Mascola, John R; Graham, Barney S; Hammer, Scott M; Sobieszczyk, Magdalena E; Corey, Lawrence; Janes, Holly E; McElrath, M Juliana; Gottardo, Raphael; Gilbert, Peter B; Tomaras, Georgia D.
Afiliação
  • Neidich SD; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Fong Y; Statistical Center for HIV/AIDS Research and Prevention.
  • Li SS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Geraghty DE; Department of Biostatistics, University of Washington, Seattle, Washington, USA.
  • Williamson BD; Statistical Center for HIV/AIDS Research and Prevention.
  • Young WC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Goodman D; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Seaton KE; Department of Biostatistics, University of Washington, Seattle, Washington, USA.
  • Shen X; Statistical Center for HIV/AIDS Research and Prevention.
  • Sawant S; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Zhang L; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • deCamp AC; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Blette BS; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Shao M; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Yates NL; Statistical Center for HIV/AIDS Research and Prevention.
  • Feely F; Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
  • Pyo CW; Statistical Center for HIV/AIDS Research and Prevention.
  • Ferrari G; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Frank I; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Karuna ST; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Swann EM; Department of Surgery and.
  • Mascola JR; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
  • Hammer SM; Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia Pennsylvania, USA.
  • Sobieszczyk ME; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Corey L; Division of AIDS and.
  • Janes HE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  • McElrath MJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  • Gottardo R; Division of Infectious Diseases, Department of Medicine, Columbia University, New York, New York, USA.
  • Gilbert PB; Division of Infectious Diseases, Department of Medicine, Columbia University, New York, New York, USA.
  • Tomaras GD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
J Clin Invest ; 129(11): 4838-4849, 2019 11 01.
Article em En | MEDLINE | ID: mdl-31589165
ABSTRACT
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the United States. Identified immune correlates of lower HIV-1 risk and a virus sieve analysis revealed that, despite lacking overall efficacy, vaccine-elicited responses exerted pressure on infecting HIV-1 viruses. To interrogate the mechanism of the antibody correlate of HIV-1 risk, we examined antigen-specific antibody recruitment of Fcγ receptors (FcγRs), antibody-dependent cellular phagocytosis (ADCP), and the role of anti-envelope (anti-Env) IgG3. In a prespecified immune correlates analysis, antibody-dependent monocyte phagocytosis and antibody binding to FcγRIIa correlated with decreased HIV-1 risk. Follow-up analyses revealed that anti-Env IgG3 breadth correlated with reduced HIV-1 risk, anti-Env IgA negatively modified infection risk by Fc effector functions, and that vaccine recipients with a specific FcγRIIa single-nucleotide polymorphism locus had a stronger correlation with decreased HIV-1 risk when ADCP, Env-FcγRIIa, and IgG3 binding were high. Additionally, FcγRIIa engagement correlated with decreased viral load setpoint in vaccine recipients who acquired HIV-1. These data support a role for vaccine-elicited anti-HIV-1 Env IgG3, antibody engagement of FcRs, and phagocytosis as potential mechanisms for HIV-1 prevention.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Receptores de IgG Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: J Clin Invest Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Receptores de IgG Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: J Clin Invest Ano de publicação: 2019 Tipo de documento: Article